InflaRx Total Liabilities 2017-2025 | IFRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

InflaRx total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

InflaRx total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.7B
Amgen (AMGN)	$161.5B
Gilead Sciences (GILD)	$142.5B
Vertex Pharmaceuticals (VRTX)	$123.1B
Bristol Myers Squibb (BMY)	$98.7B
GSK (GSK)	$81B
CSL (CSLLY)	$78.2B
Regeneron Pharmaceuticals (REGN)	$60.4B
Alnylam Pharmaceuticals (ALNY)	$42.1B
Argenex SE (ARGX)	$34.4B
BioNTech SE (BNTX)	$27.4B
Royalty Pharma (RPRX)	$20.3B
Biogen (BIIB)	$19.8B
Insmed (INSM)	$18.3B
Illumina (ILMN)	$15.8B
Genmab (GNMSF)	$14B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.3B
Exelixis (EXEL)	$12.3B
BioMarin Pharmaceutical (BMRN)	$11.3B
QIAGEN (QGEN)	$10.8B
Ascendis Pharma (ASND)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Regencell Bioscience Holdings (RGC)	$8.2B
Roivant Sciences (ROIV)	$7.9B